Research Article
Physico-Chemical Stability of Mixtures of Fosaprepitant used in Clinical Practice
Maria Amparo Martínez-Gómez1,2*, Ana Moya Gil1,2, Begoña Porta Oltra2 and Mónica Climente Martí2
1Foundation for the Promotion of Health Biomedical Research and Valencia (FISABIO), C / No 31 Sir Masco, Valencia, Spain
2Pharmacy Service, Hospital Universitario Doctor Peset, Avda. Gaspar Aguilar 90, Valencia, Spain
- *Corresponding Author:
- Maria Amparo Martinez-Gómez
Servicio de Farmaciaacy Department
Hospital Universitario Doctor Peset
Avda. Gaspar Aguilar 90, 46017, Valencia, Spain
Tel: +34961622366
E-mail: martinez_margoma@gva.es
Received date: June 27, 2014; Accepted date: July 18, 2014; Published date: July 22, 2014
Citation: Martínez-Gómez MA, Gil AM, Oltra BP, Martí MC (2014) Physico-Chemical Stability of Mixtures of Fosaprepitant used in Clinical Practice. J Anal Bioanal Tech 5: 197. doi: 10.4172/2155-9872.1000197
Copyright: © 2014 Martínez-Gómez MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Fosaprepitant dimeglumine is a new drug indicated to prevent nausea and vomiting associated with highly emetogenic cisplatin-based and moderately emetogenic cancer chemotherapy in adults. Due to its complexity in managing, since it requires reconstitution and dilution before intraveonous administration, it is necessary to evaluate physico-chemical stability of fosaprepitant at concentrations used in our routine clinical practice and at different conditions of storage to expand the information datasheet (fosaprepitant 150 mg in 150 mL of 0.9 g/dl sodium chloride (NaCl) at ambient conditions and light for 24 hours) and simplify preparation technique conforming to the fluid marketed branches. These studies should be carried out following the recommendations International Conference on Harmonisation (ICH) guidelines for evaluate stability and the criteria of the United States Pharmacopeia to maintain quality and safety of the preparation. So, stability study of fosaprepitant 150 mg in 50, 100 and 250 mL of 0.9 g/dl NaCl at room temperature/refrigerated and protective from/exposed to ambient light has been carried out. An HPLC method has been developed and validated according to ICH guidelines to evaluate chemical stability of fosaprepitant. Physical stability study has been carried out by visual inspection, measure of pH and gravimetry to control evaporation. The results shown in this paper represent the first evidence of the physico-chemical stability of the mixtures of fosaprepitant 150 mg in 50, 100 and 250 mL of 0.9 g/dl NaCl are physico-chemically stable for 7 days at room temperature (27.0 ± 0.9°C) and refrigerated (4.9 ± 1.5°C); and exposed to ambient light, 15 days at room temperature and refrigerated and protected from light and 12 days fosaprepitant reconstituted and stored refrigerated and exposed to light.